stockrow
Friday 6 November 2026
Export PLYX’s income statement to Excel — free account
Polaryx Therapeutics, Inc.
PLYX Healthcare Biotechnology
1.80
0.00
0.00%
Follow PLYX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | (30) | (9) | (10) | (70.4%) | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | — | (30) | (9) | (14) | (70.4%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | — | (0.89) | (0.19) | (0.22) | (78.5%) | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (0.08) | (0.09) | (0.17) | +15.4% | ||||||
| Capex | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (0.08) | (0.09) | (0.17) | +15.4% | ||||||
| Book value | — | — | — | — | — | — | — | — | 0.14 | 0.10 | 0.23 | (27.1%) | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 34 | 45 | 46 | +32.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (3) | (4) | (8) | +53.3% | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (3) | (4) | (8) | +53.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 5 | 5 | 11 | (3.1%) | |||||
| Net debt | — | — | — | — | — | — | — | — | (5) | (5) | (12) | +11.3% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | 5 | 5 | 11 | (3.1%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (176.68) | (169.05) | (176.7) pt | |||||
| ROIC | — | — | — | — | — | — | — | — | (2,989.01) | 0.00 | 0.00 | +2,989.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | (193.70) | 0.00 | (193.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 11 | 11 | — | 0.0% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Polaryx Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SEER Seer, Inc. | $94.1M | — (loss-making) | — (loss-making) | −23.43% (below 0%: shrinking) | n/m | +36.73% (above 0%: growing) | 48.55% | (542.91%) | Compare |
| VXRT VAXART, INC. | $92.4M | 2.8× | — (loss-making) | −85.33% (below 0%: shrinking) | n/m | +117.38% (above 0%: growing) | 100.00% | (162.74%) | Compare |
| KZIA Novogen Limited | $92.4M | — (loss-making) | — (loss-making) | — | −32.67% (below 0%: shrinking) | −51.71% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PLYX Polaryx Therapeutics, Inc. | $89.7M | — (loss-making) | — | — | n/m | −93.09% (below 0%: shrinking) | — | 0.00% | |
| EQ Equillium, Inc. | $88.8M | — (loss-making) | — (loss-making) | −52.32% (below 0%: shrinking) | n/m | −38.67% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| GNLX Genelux Corporation | $88.7M | — (loss-making) | — (loss-making) | — | n/m | −11.18% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| TNXP Tonix Pharmaceuticals Holding Corp. | $87.6M | — (loss-making) | — (loss-making) | +577.88% (above 0%: growing) | n/m | −178.84% (below 0%: shrinking) | 94.81% | (314.05%) | Compare |
| NRXS Neuraxis, Inc. | $86.2M | — (loss-making) | — (loss-making) | +115.71% (above 0%: growing) | n/m | +29.76% (above 0%: growing) | 85.87% | (110.16%) | Compare |
| RLYB Rallybio Corporation | $85.6M | 3.3× | — (loss-making) | 0.00% | n/m | +65.25% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $88.7M | — | — | −11.71% | — | +9.29% | 97.41% | (55.08%) |
Polaryx Therapeutics, Inc. (PLYX) Latest News
No news at this impact. Lower the threshold for more.